Search results for "Gate"

showing 10 items of 1811 documents

Novel haptens and monoclonal antibodies with subnanomolar affinity for a classical analytical target, ochratoxin A

2018

Ochratoxin A is a potent toxic fungal metabolite whose undesirable presence in food commodities constitutes a problem of public health, so it is strictly regulated and controlled. For the first time, two derivatives of ochratoxin A (OTAb and OTAd) functionalized through positions other than the native carboxyl group of the mycotoxin, have been synthesized in order to better mimic, during the immunization process, the steric and conformational properties of the target analyte. Additionally, two conventional haptens making use of that native carboxyl group for protein coupling (OTAe and OTAf) were also prepared as controls for the purpose of comparison. The immunological performance in rabbit…

Ochratoxin AAnalytemedicine.drug_classlcsh:MedicineEnzyme-Linked Immunosorbent AssayMonoclonal antibody01 natural sciencesArticlechemistry.chemical_compound0404 agricultural biotechnologymedicineMycotoxinlcsh:ScienceOchratoxinMultidisciplinaryMolecular Structurebiology010401 analytical chemistrylcsh:RAntibodies Monoclonalfood and beverages04 agricultural and veterinary sciencesOchratoxins040401 food science0104 chemical scienceschemistryBiochemistrybiology.proteinlcsh:QAntibodyHaptensHaptenConjugate
researchProduct

Simultaneous detection of the main black aspergilli responsible for ochratoxin A (OTA) contamination in grapes by multiplex real-time polymerase chai…

2009

9 pages.

Ochratoxin AAspergillus niger aggregateGrapesHealth Toxicology and MutagenesisFood ContaminationWineAspergillus carbonariusBiologyToxicologyPolymerase Chain ReactionSensitivity and SpecificityMelting curve analysisReal-time polymerase chain reactionlaw.inventionMicrobiology03 medical and health scienceschemistry.chemical_compoundSpecies SpecificitylawTaqManVitisDNA FungalOchratoxinPolymerase chain reaction030304 developmental biology2. Zero hunger0303 health sciencesMycotoxinChromatography030306 microbiologyPublic Health Environmental and Occupational HealthFungal geneticsOchratoxin AGeneral ChemistryGeneral MedicineMycotoxinsSpores FungalOchratoxins3. Good healthAspergillusReal-time polymerase chain reactionchemistrySpainCarcinogensSYBR Green IAspergillus tubingensisPolyketide synthaseFood Science
researchProduct

Synthesis of Enantiopure ω-(4-Fluorophenyl)-6,11-Methylene Lipoxin B4 Methyl Ester

2021

AbstractThe synthesis of Lipoxin B4 analogues (LXB4) to gain access to stabilized inflammation-resolving compounds is an active field of research. Focusing on variation and stabilization of the conjugated E,Z,E,E C6–C13 tetraene moiety of natural LXB4, a methylene bridge introduced between C6 and C11 suppresses any Z/E isomerization of the C8–C9 olefin. Furthermore, rapid ω-oxidation (C20) should be avoided by replacing the C18–C20 segment by an aromatic moiety. Optically active C1–C12 building blocks were accessed from methyl cycloheptatriene-1-carboxylate (C6–C11, C21) and glutaryl chloride (C1–C5) as described earlier. The ω-segment was generated via a five-step sequence starting from 4-…

Olefin fiber010405 organic chemistryStereochemistryOrganic ChemistryMethylene bridgeConjugated system010402 general chemistry01 natural sciencesCatalysis0104 chemical scienceschemistry.chemical_compoundEnantiopure drugchemistryMoietyChelationMethyleneIsomerizationSynthesis
researchProduct

Tandem cross enyne metathesis (CEYM)–intramolecular Diels–Alder reaction (IMDAR). An easy entry to linear bicyclic scaffolds

2015

A new tandem cross enyne metathesis (CEYM)–intramolecular Diels–Alder reaction (IMDAR) has been carried out. It involves conjugated ketones, esters or amides bearing a remote olefin and aromatic alkynes as the starting materials. The overall process enables the preparation of a small family of linear bicyclic scaffolds in a very simple manner with moderate to good levels of diastereoselectivity. This methodology constitutes one of the few examples that employ olefins differently than ethylene in tandem CEYM–IMDAR protocols.

Olefin fiberBicyclic moleculeTandemChemistryOrganic ChemistryConjugated systemEnyne metathesisCombinatorial chemistryFull Research Paperlcsh:QD241-441Chemistrylcsh:Organic chemistryCascade reactionDiels–Alder reactionIntramolecular forcebicyclic frameworkscross enyne metathesisOrganic chemistrylcsh:Qtandem reactionlcsh:ScienceDiels-Alder reactionDiels–Alder reactionBeilstein Journal of Organic Chemistry
researchProduct

ChemInform Abstract: Tandem Cross Enyne Metathesis (CEYM)-Intramolecular Diels-Alder Reaction (IMDAR). An Easy Entry to Linear Bicyclic Scaffolds.

2015

A new tandem cross enyne metathesis (CEYM)–intramolecular Diels–Alder reaction (IMDAR) has been carried out. It involves conjugated ketones, esters or amides bearing a remote olefin and aromatic alkynes as the starting materials. The overall process enables the preparation of a small family of linear bicyclic scaffolds in a very simple manner with moderate to good levels of diastereoselectivity. This methodology constitutes one of the few examples that employ olefins differently than ethylene in tandem CEYM–IMDAR protocols.

Olefin fiberTandemBicyclic moleculeChemistryIntramolecular forceSalt metathesis reactionGeneral MedicineConjugated systemEnyne metathesisCombinatorial chemistryDiels–Alder reactionChemInform
researchProduct

Distribution of the A3 subunit of the cyclic nucleotide-gated ion channels in the main olfactory bulb of the rat.

2008

Previous data suggest that cyclic GMP (cGMP) signaling can play key roles in the circuitry of the olfactory bulb (OB). Therefore, the expression of cGMP-selective subunits of the cyclic nucleotide-gated ion channels (CNGs) can be expected in this brain region. In the present study, we demonstrate a widespread expression of the cGMP-selective A3 subunit of the cyclic nucleotide-gated ion channels (CNGA3) in the rat OB. CNGA3 appears in principal cells, including mitral cells and internal, medium and external tufted cells. Moreover, it appears in two populations of interneurons, including a subset of periglomerular cells and a group of deep short-axon cells. In addition to neurons, CNGA3-immu…

Olfactory systemMaleDoublecortin ProteinRostral migratory streamPeriglomerular cellPopulationCyclic Nucleotide-Gated Cation ChannelsNerve Tissue ProteinsOlfactionBiologyOlfactory nervemedicineAnimalsRats Wistareducationgamma-Aminobutyric Acideducation.field_of_studyGeneral NeuroscienceOlfactory BulbCell biologyOlfactory bulbRatsmedicine.anatomical_structurenervous systemMicroscopy FluorescenceNeurogliaNeuroscienceNeuroscience
researchProduct

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

2009

Abstract Background In resectable rectal cancer trials, pathological parameters are early preoperative treatment efficacy measures. Their validation as surrogate end points for long-term clinical outcomes would allow to reduce trial duration. The aim was to evaluate potential surrogates for overall survival (OS) and local control (LC) in preoperative T3/T4 rectal cancer trials. Candidate variables included ypT and ypN stages, T downstaging, tumor regression grade (TRG), and circumferential resection margin (CRM) status. Patients and methods In the Federation Francophone de Cancerologie Digestive (FFCD) 9203 trial, 742 eligible patients were randomly assigned to receive preoperative radiothe…

OncologyAdultMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAdenocarcinomaPreoperative careInternal medicinemedicineHumansNeoadjuvant therapyAgedRandomized Controlled Trials as TopicTumor Regression GradeAged 80 and overbusiness.industrySurrogate endpointRectal NeoplasmsHematologyMiddle Agedmedicine.diseaseChemotherapy regimenCombined Modality TherapyConfidence intervalNeoadjuvant TherapySurgeryClinical trialSurvival RateTreatment OutcomeOncologyFemaleNeoplasm Recurrence LocalbusinessBiomarkersAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.

2021

Abstract The COVID-19 pandemic affected millions of people globally with lasting effects on society, patients, investigators and health institutions. Clinical trials, our best tool to improve cancer treatment for patients through testing the clinical value of a new treatment, have been affected by the pandemic. The pandemic footprint represents both a risk of compromising development of new therapies and an opportunity to elicit discussion over a portfolio of broader reforms, applicable irrespective of pandemics, in order to improve the design and implementation of clinical trials in oncology. The administrative load should be reduced, without affecting the quality of research and principle…

OncologyCancer ResearchTelemedicinemedicine.medical_specialtyOncologiamedia_common.quotation_subjectMedical Oncology:profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES]Quality of life (healthcare):características del estudio::estudio clínico::ensayo clínico [CARACTERÍSTICAS DE PUBLICACIONES]:Study Characteristics::Clinical Study::Clinical Trial [PUBLICATION CHARACTERISTICS]Internal medicinePandemic:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]medicinePandèmia de COVID-19 2020-HumansQuality (business):Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS]Pandemicsmedia_commonCOVID-19; Humans; Medical Oncology; Pandemics/prevention & control; SARS-CoV-2; TelemedicineSurrogate endpointSARS-CoV-2COVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]World populationTelemedicineClinical trialEditorialOncologyGood clinical practiceBusinessAssaigs clínicsESMO open
researchProduct

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

2010

Abstract Background Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in digestive oncology. The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists. Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL). Methods In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of …

OncologyCancer ResearchTime FactorsDigestive System Neoplasms[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of lifeSurveys and QuestionnairesMedicine030212 general & internal medicineMESH: Treatment OutcomeResponse rate (survey)MESH : Evidence-Based MedicineClinical Trials as TopicEvidence-Based MedicineMESH: Endpoint DeterminationMESH: Research DesignMESH : QuestionnairesMESH : Research Designlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMESH: Reproducibility of Resultsmedicine.anatomical_structureTreatment OutcomeOncologyResearch Design030220 oncology & carcinogenesisData Interpretation StatisticalMESH: Survival AnalysisMESH : Disease-Free SurvivalMESH : Endpoint DeterminationFranceMESH : Time FactorsResearch Articlemedicine.medical_specialtyMESH: Clinical Trials as TopicEndpoint DeterminationRectum[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Treatment Outcomelcsh:RC254-282Disease-Free Survival03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneticsHumansMESH : Data Interpretation StatisticalMESH : FranceSurvival analysisMESH: Humansbusiness.industrySurrogate endpointMESH: Digestive System NeoplasmsMESH : Reproducibility of ResultsMESH: QuestionnairesMESH : HumansMESH: Time FactorsCancerReproducibility of ResultsMESH: Quality of LifeMESH : Quality of Lifemedicine.diseaseSurvival AnalysisMESH : Clinical Trials as TopicMESH: FranceLocalized diseaseEndpoint DeterminationMESH: Disease-Free SurvivalQuality of LifeMESH : Digestive System NeoplasmsMESH : Survival AnalysisbusinessMESH: Data Interpretation StatisticalMESH: Evidence-Based MedicineBMC Cancer
researchProduct

Assessment of treatment response in hepatocellular carcinoma: a review of the literature

2013

Hepatocellular carcinoma (HCC) has a high incidence all over the world. Even if the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and could have a key role in clinical management. Since 1950 several radiological response criteria have been applied; however, it was not until 2000 that specific criteria for HCC were introduced by the European Association for the Study of the Liver (EASL), and these were then standardized in 2010 with the development of the modified Response Evaluation Criteria for Solid Tumors (mRECIST) for HCC. The purpose of this brief review is to compare data in literature regarding the application an…

OncologyCancer ResearchTreatment responsemedicine.medical_specialtyCarcinoma HepatocellularLiver Function TestsInternal medicineClinical endpointHumansMedicineResponse criteriaNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industrySurrogate endpointIncidence (epidemiology)Liver NeoplasmsGeneral MedicinePrognosismedicine.diseaseSurvival Analysisdigestive system diseasesRadiographyClinical PracticeTreatment OutcomeOncologyRadiological weaponHepatocellular carcinomabusinessFuture Oncology
researchProduct